Loading
MS
Molecure S.A. Stock: price and insider trades · Poland
No insider purchase over the last 90 days. The latest, by Szumowski Investments Sp. z o.o., was filed 30 Mar 2026.
Molecure S.A.: what insiders have been doing
Molecure S.A. is a Health Care company. Its directors and officers file their transactions with KNF. Over the twelve months to 23 October 2026, 2 filings were filed, from 1 insider.
Both sides are active: 1 purchase worth €1.2M and 1 sale worth €1.2M, from 1 insider and 1 insider respectively. Taken together, the sales exceed the purchases by €4,600. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a sale of €1.2M by Szumowski Investments Sp. z o.o., published on 26 March 2026.
Across the 554 companies tracked on its exchange, the median is 3 filings; at 2 filings, this issuer sits below that mark. The full history, which starts in 2026, counts 1 purchase against 1 sale.
The last purchase on record was published on 30 March 2026, which is 207 days ago.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€1M
1 ops. · all time
Sell Volume
€1M
1 ops. · all time
Who traded when
BuySaleSzumowski Investments Sp. z o.o.1 buy1 sale
Since the insiders bought
- +2.8%Entry PLN 5.35 · Close at T+90 PLN 5.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Molecure S.A. Strong Buy (bullish), based on 2 analysts. Average price target: PLN 13.10.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
PLN 6.16
Analyst consensus
2 analystsStrong buy
PLN 11.20Target PLN 13.10(+113%)PLN 15.00
Income statement
Gross profit-PLN 3.4M
EBITDA-PLN 27.5M
Net income-PLN 31.3M-240.6% margin
Valuation
P/Book1.4x
Beta1.00
Balance sheet & cash
Market capPLN 152.3M
Total debtPLN 7.2M
Free Cash Flow-PLN 80.8M
Debt / Equity6%
Profitability & ownership
ROE-16.3%
% insiders29.3%
% institutions9.3%
Last declaration on 30 March 2026
Declarations2 total
1,000,000 shares@ PLN 5.0049.9% of flowShareWSEKNF:node/717983
Canonical exit: 28 Jun 2026 (T+90)
1,000,000 shares@ PLN 5.0050.1% of flowShareWSEKNF:node/717769
2 of 2 declarations
About Molecure S.A.
Molecure S.A. is a company listed on the XWAR market, specializing in the development of innovative drugs. It focuses on research and development of treatments for serious diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
